Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas

Abstract excerpt

BACKGROUND: Dopamine agonists (DAs) are the first-line treatment for prolactinomas, which account for 25-30% of functioning pituitary adenomas, and bromocriptine (BRC) is the only commercially available DAs in China. However, tumors are resistant to therapy in 5-18% of patients. METHODS: The exomes of six responsive prolactinomas and six resistant prolactinomas were analyzed by whole-exome sequencing. RESULTS:...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adrenal and Paraganglionic Tumors
• Share to Hypothalamic control of reproductive hormones
• Share to Pituitary Gland Disorders and Treatments